Skip to content
Research archive

Research Articles

Randomized Controlled Trial

Safety and efficacy of direct versus conventional transfer to angiography suite in patients with severe acute stroke treated with thrombectomy (DIRECT ANGIO) in France: a multicentre, open-label, blinded-endpoint, randomised controlled trial.

Direct Angiography Transfer Raises Haemorrhage Risk With No Functional Benefit in Severe Stroke — In a randomised trial stopped early for safety reasons, bypassing pre-treatment imaging and transferring suspected large vessel occlusion stroke patients directly to the angiography suite was associated with an approximately elevenfold higher risk of symptomatic intracranial haemorrhage compared with the conventional imaging-first pathway (15% vs 0%; adjusted OR 11.

Apr 1, 2026 · Lancet Neurol · Cardiology
86
Research Article

Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial.

Sitagliptin/Empagliflozin Fixed-Dose Combinations Significantly Reduce HbA1c in Metformin-Treated Korean Adults — Both fixed-dose combinations of sitagliptin and empagliflozin produced statistically significant reductions in HbA1c compared with placebo at 24 weeks — approximately 0.

Mar 31, 2026 · Diabetes Obes Metab · Metabolism
83
Research Article

Vaginal microbiota transplantation for treatment of vaginal dysbiosis without the use of antibiotics: a double-blind, randomised controlled trial in women with vaginal dysbiosis.

Vaginal Microbiota Transplant Without Pretreatment Fails to Resolve Dysbiosis in RCT — In a double-blind randomised controlled trial, vaginal microbiota transplantation (VMT) administered without antibiotic pretreatment showed no statistically significant advantage over placebo in resolving vaginal dysbiosis, with the hazard ratio slightly favouring placebo and a wide confidence interval indicating substantial imprecision (HR 0.

Mar 31, 2026 · Lancet Microbe · Infectious Diseases
85
Research Article

Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial.

Polymyxin B Haemoadsorption Shows High Probability of Mortality Benefit in Endotoxic Septic Shock — In a phase 3 Bayesian randomised trial, polymyxin B haemoadsorption was associated with lower 28-day mortality compared with standard care alone in patients with endotoxic septic shock (39% vs 45%; posterior probability of benefit 95.

Mar 30, 2026 · Lancet Respir Med · New Therapies
88
Clinical Trial

Shexiang Baoxin pill in patients with stable coronary artery disease and reduced eGFR: Subgroup analysis of phase IV randomized trial.

MUSKARDIA Shows Non-Significant Cardiovascular Trend in Stable CAD Patients With Reduced Kidney Function — In patients with stable coronary artery disease and reduced kidney function, Shexiang Baoxin pill (MUSKARDIA) did not significantly reduce major adverse cardiovascular events compared to placebo, showing an imprecise roughly 29% lower relative risk that did not reach statistical significance (HR 0.

Mar 30, 2026 · Phytomedicine · Cardiology
92
Randomized Controlled Trial

Effect of Essential Phospholipids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial.

Essential Phospholipids Reduce Hepatic Steatosis and Improve Glycaemic Control in MASLD — In a double-blind, placebo-controlled trial, essential phospholipid (EPL) treatment significantly reduced hepatic steatosis measured by Controlled Attenuation Parameter (CAP) score compared with placebo at six months (p = 0.

Mar 29, 2026 · Liver Int · Metabolism
84